Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Coherus Oncology (CHRS) EBITDA Margin (2016 - 2025)

Coherus Oncology's EBITDA Margin history spans 12 years, with the latest figure at 359.9% for Q4 2025.

  • For Q4 2025, EBITDA Margin rose 22699.0% year-over-year to 359.9%; the TTM value through Dec 2025 reached 429.51%, down 21038.0%, while the annual FY2025 figure was 429.51%, 32706.0% up from the prior year.
  • EBITDA Margin for Q4 2025 was 359.9% at Coherus Oncology, up from 383.14% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 27.58% in Q2 2021 and bottomed at 2937.05% in Q1 2024.
  • The 5-year median for EBITDA Margin is 155.86% (2022), against an average of 348.33%.
  • The largest annual shift saw EBITDA Margin plummeted -272819bps in 2024 before it soared 233914bps in 2025.
  • A 5-year view of EBITDA Margin shows it stood at 53.91% in 2021, then crashed by -111bps to 113.54% in 2022, then skyrocketed by 34bps to 75.29% in 2023, then plummeted by -680bps to 586.89% in 2024, then soared by 39bps to 359.9% in 2025.
  • Per Business Quant, the three most recent readings for CHRS's EBITDA Margin are 359.9% (Q4 2025), 383.14% (Q3 2025), and 443.59% (Q2 2025).